LV10303B - Method for elimination of breast cancer cells - Google Patents

Method for elimination of breast cancer cells Download PDF

Info

Publication number
LV10303B
LV10303B LVP-93-1060A LV931060A LV10303B LV 10303 B LV10303 B LV 10303B LV 931060 A LV931060 A LV 931060A LV 10303 B LV10303 B LV 10303B
Authority
LV
Latvia
Prior art keywords
protoporphyrin
cells
protoporphyrinogen
inhibitor
compound
Prior art date
Application number
LVP-93-1060A
Other languages
English (en)
Latvian (lv)
Other versions
LV10303A (lv
Inventor
Halling Blaik Philippe
Witkowski Debra Ann
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of LV10303A publication Critical patent/LV10303A/xx
Publication of LV10303B publication Critical patent/LV10303B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-93-1060A 1988-12-12 1993-09-09 Method for elimination of breast cancer cells LV10303B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28515188A 1988-12-12 1988-12-12
US33500789A 1989-04-07 1989-04-07
US35133189A 1989-05-03 1989-05-03
PCT/US1989/005599 WO1990006748A2 (en) 1988-12-12 1989-12-08 Use of certain herbicides in cancer treatment and production of protoporphyrin ix

Publications (2)

Publication Number Publication Date
LV10303A LV10303A (lv) 1994-10-20
LV10303B true LV10303B (en) 1995-08-20

Family

ID=27403508

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1060A LV10303B (en) 1988-12-12 1993-09-09 Method for elimination of breast cancer cells

Country Status (28)

Country Link
EP (1) EP0447491B1 (fi)
JP (1) JP2545000B2 (fi)
KR (1) KR930003116B1 (fi)
AR (1) AR243605A1 (fi)
AT (1) AT400520B (fi)
AU (1) AU633537B2 (fi)
BR (1) BR8907817A (fi)
CA (1) CA2004979A1 (fi)
CH (1) CH681779A5 (fi)
DE (2) DE3991484C2 (fi)
DK (1) DK110791A (fi)
EG (1) EG18822A (fi)
ES (1) ES2051675T3 (fi)
FI (1) FI912784A0 (fi)
GB (1) GB2247404B (fi)
GR (1) GR1000609B (fi)
HU (1) HUT58202A (fi)
IE (1) IE62621B1 (fi)
IL (1) IL92622A (fi)
LU (1) LU87949A1 (fi)
LV (1) LV10303B (fi)
MC (1) MC2171A1 (fi)
NO (1) NO912228D0 (fi)
NZ (1) NZ231658A (fi)
OA (1) OA09362A (fi)
PT (1) PT92546B (fi)
SE (1) SE505938C2 (fi)
WO (1) WO1990006748A2 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298502A (en) * 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
US5132101A (en) * 1990-05-04 1992-07-21 Cytopharm, Inc. Acetylene-cumulene porphycene compounds for photodynamic therapy
US5244671A (en) * 1991-01-29 1993-09-14 Cytopharm, Inc. Derivatives of porphycene for photodynamic therapy of cancer
US5179120A (en) * 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
GB9318841D0 (en) * 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6084155A (en) * 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
BR9707783A (pt) * 1996-02-28 1999-07-27 Novartis Ag Promotores provenientes de genes para protoporfirnogênio oxidase em vegetais
JPH10330359A (ja) * 1997-03-31 1998-12-15 Nippon Bayeragrochem Kk フエニルアセチレン誘導体及び除草剤
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
SI2443102T1 (sl) 2009-06-19 2013-08-30 Basf Se Herbicidni benzoksazinoni
EP2496573B1 (en) * 2009-11-02 2015-07-01 Basf Se Herbicidal tetrahydrophthalimides
CN103221409B (zh) * 2010-10-01 2016-03-09 巴斯夫欧洲公司 除草的苯并*嗪酮类
EP2651226B1 (en) 2010-12-15 2016-11-23 Basf Se Herbicidal compositions
CN102875569A (zh) * 2012-09-27 2013-01-16 南开大学 具有除草活性和抗肝癌活性的异噁唑并嘧啶酮(或三嗪酮)类化合物
US11185075B2 (en) * 2016-12-16 2021-11-30 Basf Se Herbicidal phenyltriazolinones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393071A (en) * 1975-03-17 1983-07-12 Naoharu Fujii Method of treating gastric, mammary, lung and uterus tumors
US4404019A (en) * 1980-12-24 1983-09-13 Sumitomo Chemical Company, Limited 3-Chloro-1-phenyl-1,2,4-triazolin-5-ones and their use as herbicides
CH651029A5 (de) * 1980-12-25 1985-08-30 Nihon Nohyaku Co Ltd Triazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende herbizide mittel.
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4755217A (en) * 1987-01-15 1988-07-05 Fmc Corporation Triazinedione herbicides
US4761174A (en) * 1987-04-14 1988-08-02 Fmc Corporation Triazolin-5-one herbicides

Also Published As

Publication number Publication date
GR890100817A (en) 1991-03-15
NZ231658A (en) 1992-05-26
BR8907817A (pt) 1991-10-22
WO1990006748A2 (en) 1990-06-28
GB9110472D0 (en) 1991-11-27
GB2247404A (en) 1992-03-04
AR243605A1 (es) 1993-08-31
HUT58202A (en) 1992-02-28
IE893925L (en) 1990-06-12
SE505938C2 (sv) 1997-10-27
DE3991484T (fi) 1991-11-21
SE9101807D0 (sv) 1991-06-12
OA09362A (en) 1992-09-15
DK110791A (da) 1991-08-12
FI912784A0 (fi) 1991-06-10
IL92622A (en) 1996-05-14
ES2051675T1 (es) 1994-07-01
ES2051675T3 (es) 1994-11-01
MC2171A1 (fr) 1992-05-22
EP0447491A1 (en) 1991-09-25
IE62621B1 (en) 1995-02-22
PT92546A (pt) 1990-06-29
PT92546B (pt) 1995-09-12
JPH04501420A (ja) 1992-03-12
DE3991484C2 (de) 1995-02-23
EP0447491B1 (en) 1993-08-11
GR1000609B (el) 1992-08-31
NO912228L (no) 1991-06-11
CA2004979A1 (en) 1990-06-12
LV10303A (lv) 1994-10-20
SE9101807L (sv) 1991-06-12
CH681779A5 (fi) 1993-05-28
LU87949A1 (fr) 1991-12-16
AU4822290A (en) 1990-07-10
DK110791D0 (da) 1991-06-11
KR930003116B1 (ko) 1993-04-19
GB2247404B (en) 1993-03-03
EG18822A (en) 1994-09-29
KR910700046A (ko) 1991-03-13
WO1990006748A3 (en) 1990-10-04
IL92622A0 (en) 1990-08-31
ATA903489A (de) 1995-06-15
NO912228D0 (no) 1991-06-11
AT400520B (de) 1996-01-25
AU633537B2 (en) 1993-02-04
JP2545000B2 (ja) 1996-10-16

Similar Documents

Publication Publication Date Title
LV10303B (en) Method for elimination of breast cancer cells
Lopatina et al. Abortive infection: bacterial suicide as an antiviral immune strategy
Qin et al. Microbe‐mediated extracellular and intracellular mineralization: environmental, industrial, and biotechnological applications
Ahmed et al. Future prospects of antibacterial metal nanoparticles as enzyme inhibitor
Schwerdtle et al. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA
Mishra et al. Why do bacteria use so many enzymes to scavenge hydrogen peroxide?
Proctor Respiration and small colony variants of Staphylococcus aureus
Lippert III Vascular disrupting agents
Lin Antibiotic growth promoters enhance animal production by targeting intestinal bile salt hydrolase and its producers
Imlay Pathways of oxidative damage
Wilkinson et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes
Slawson et al. Germanium and silver resistance, accumulation, and toxicity in microorganisms
Leanse et al. Evaluating the potential for resistance development to antimicrobial blue light (at 405 nm) in Gram-negative bacteria: in vitro and in vivo studies
JP2008515405A5 (fi)
Chen et al. Effect of metal ions on the activity of green crab (Scylla serrata) alkaline phosphatase
Kubiak et al. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy
Landry et al. Iron–sulfur proteins are the major source of protein-bound dinitrosyl iron complexes formed in Escherichia coli cells under nitric oxide stress
Rodriguez-Valera General and applied aspects of halophilic microorganisms
Bauer et al. Helicobacter pylori protects oncogenically transformed cells from reactive oxygen species-mediated intercellular induction of apoptosis
Schloss Modern aspects of enzyme inhibition with particular emphasis on reaction-intermediate analogs and other potent, reversible inhibitors
Gopal et al. Reactive dirty fragments: implications for tuberculosis drug discovery
Yamada et al. Development of a CRISPR interference system for selective gene knockdown in Acidithiobacillus ferrooxidans
Aunins et al. Isolating the Escherichia coli transcriptomic response to superoxide generation from cadmium chalcogenide quantum dots
Imlay Redox pioneer: Professor Irwin Fridovich
Tajima The effects of tungstophosphate and tungstosilicate on various stress promoters transformed in Escherichia coli